MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3 Retraction in /10.3892/mmr.2021.12294

Zhao,Shuzhen; Wen,Zhengfang; Liu,Shanshan; Liu,Ying; Li,Xiaorui; Ge,Yanna; Li,Shaoru

doi:10.3892/mmr.2015.3826

September-2015 Volume 12 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 12 Issue 3

Full Size Image

Article

MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3

Retraction in: /10.3892/mmr.2021.12294

Authors:
- Shuzhen Zhao
- Zhengfang Wen
- Shanshan Liu
- Ying Liu
- Xiaorui Li
- Yanna Ge
- Shaoru Li
View Affiliations / Copyright

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Pages: 3923-3929
|
Published online on: May 25, 2015

https://doi.org/10.3892/mmr.2015.3826
Expand metrics +

Abstract

MicroRNAs (miRs) are a class of non-coding RNAs that function as key regulators of gene expression at the post-transcriptional level. miR-148a has been suggested to be associated with human ovarian cancer, however, the detailed functions of miR‑148a in ovarian cancer remain to be fully elucidated. The present study aimed to investigate the regulatory mechanism of miR-148a in ovarian cancer cells. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were conducted to examine the RNA and protein levels, respectively. The luciferase reporter assay was used to determine the target relationship. Cell proliferation and apoptosis assays were additionally conducted. The present study demonstrated that miR‑148a inhibited cell proliferation and promoted the paclitaxel‑induced apoptosis of ovarian cancer cells. Furthermore, protein disulfide isomerase family A, member 3 (PDIA3) was identified as a target gene of miR‑148a. A fluorescent reporter assay was performed to confirm that miR‑148a was able to directly bind to the 3'‑untranslated region of PDIA3 mRNA. In addition, miR‑148a was frequently downregulated in ovarian cancer tissue, whereas the expression levels of PDIA3 were increased. Knockdown of PDIA3 significantly inhibited the proliferation and promoted the paclitaxel‑induced apoptosis of the ovarian cancer cells, whereas overexpression of PDIA3 had the opposite effects. Therefore, the results of the present study suggested that miR‑148a inhibited the proliferation and promoted the paclitaxel‑induced apoptosis of ovarian cancer cells, and this may be partly attributed to direct targeting of PDIA3.

View Figures

View References

1	Choi JH, Wong AS, Huang HF and Leung PC: Gonadotropins and ovarian cancer. Endocr Rev. 28:440–461. 2007. View Article : Google Scholar : PubMed/NCBI
2	Shylasree TS, Bryant A and Athavale R: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev. 2:CD0062462013.PubMed/NCBI
3	Llauradó M, Majem B, Altadill T, et al: MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol. 390:73–84. 2014. View Article : Google Scholar : PubMed/NCBI
4	Park SH, Song JY, Kim YK, et al: Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol. 44:637–646. 2014.PubMed/NCBI
5	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Bienertova-Vasku J, Sana J and Slaby O: The role of microRNAs in mitochondria in cancer. Cancer Lett. 336:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
9	Heo MJ, Kim YM, Koo JH, et al: microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 5:2792–2806. 2014.PubMed/NCBI
10	Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhang JP, Zeng C, Xu L, Gong J, Fang JH and Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene. 33:4069–4076. 2014. View Article : Google Scholar
12	Zhou X, Zhao F, Wang ZN, et al: Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep. 27:447–454. 2012.
13	Hou F, Wang L, Wang H, et al: Elevated gene expression of S100A12 is correlated with the predominant clinical inflammatory factors in patients with bacterial pneumonia. Mol Med Rep. 11:4345–4352. 2015.PubMed/NCBI
14	Chay D, Cho H, Lim BJ, et al: ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. Int J Oncol. 37:399–412. 2010.PubMed/NCBI
15	Ménoret A, Drew DA, Miyamoto S, et al: Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells. Mol Carcinog. 53(Suppl 1): E11–E22. 2014. View Article : Google Scholar
16	Murata T, Takayama K, Katayama S, et al: miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 13:356–361. 2010. View Article : Google Scholar : PubMed/NCBI
17	Xia J, Guo X, Yan J and Deng K: The role of miR-148a in gastric cancer. J Cancer Res Clin Oncol. 140:1451–1456. 2014. View Article : Google Scholar : PubMed/NCBI
18	Long XR, He Y, Huang C and Li J: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol. 44:1915–1922. 2014.PubMed/NCBI
19	Fujita Y, Kojima K, Ohhashi R, et al: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
20	Turano C, Gaucci E, Grillo C and Chichiarelli S: ERp57/GRP58: A protein with multiple functions. Cell Mol Biol Lett. 16:539–563. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chung H, Cho H, Perry C, et al: Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. Biomarkers. 18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
22	Gaucci E, Altieri F, Turano C and Chichiarelli S: The protein ERp57 contributes to EGF receptor signaling and internalization in MDA-MB-468 breast cancer cells. J Cell Biochem. 114:2461–2470. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cicchillitti L, Di Michele M, Urbani A, et al: Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: The role of ERp57. J Proteome Res. 8:1902–1912. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lwin ZM, Yip GW, Chew FT and Bay BH: Downregulation of ER60 protease inhibits cellular proliferation by inducing G/S arrest in breast cancer cells in vitro. Anat Rec (Hoboken). 295:1410–416. 2012. View Article : Google Scholar
25	Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D and Scambia G: Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: The involvement of specific conformational states of beta-actin. Int J Oncol. 37:445–454. 2010. View Article : Google Scholar : PubMed/NCBI